Crescent Biopharma Inc — Financial Statements (NASDAQ:CBIO)

Financials

Total revenue 10.16 M1.16 M75 K10 K-46.65 K10.84 M — Gross profit 10.16 M1.16 M75 K10 K-46.65 K10.84 M — Operating expenses 61.67 M64.61 M47.48 M39.29 M40.04 M163.48 M 187.13 M Selling/general/admin expenses 16.74 M17.12 M19.09 M19.21 M18.25 M25.39 M 25.39 M Research & development 44.93 M47.49 M28.39 M20.07 M14.26 M138.09 M 159.31 M Operating income -51.51 M-63.45 M-47.4 M-39.28 M-40.04 M152.63 M 185.88 M Non-Operating Income, Total ————2.16 M2.88 M — Interest expense, net of interest capitalized —————4.37 M — Non-Operating Income, excl. Interest Expenses ————2.16 M-1.5 M — Unusual income/expense —————— — Pretax income -51.51 M-63.45 M-47.4 M-39.28 M-37.88 M151.94 M 155.19 M Equity in earnings —————— — Taxes —————2 M 69.52 M Non-controlling/minority interest —————— — After tax other income/expense —————— — Net income before discontinued operations -51.03 M-63.43 M-46.69 M-36.9 M-37.88 M153.94 M 43.66 M Discontinued operations —————— — Net income -51.03 M-63.43 M-46.69 M-36.9 M-37.88 M153.94 M 43.66 M Dilution adjustment —————— — Preferred dividends —————— — Diluted net income available to common stockholders -51.03 M-63.43 M-46.69 M-36.9 M-37.88 M133.45 M 50.1 M Basic earnings per share (Basic EPS) —-18.45-13.35-0.58-0.59— — Diluted earnings per share (Diluted EPS) —-18.45-13.35-0.58-0.5996.25 — Average basic shares outstanding —3.43 M3.5 M63.34 M64.48 M— — Diluted shares outstanding —3.43 M3.5 M63.34 M64.48 M1.6 M 69.58 M EBITDA —————— — EBIT —————— — Cost of revenue —————— — Other cost of goods sold —————— — Depreciation & amortization (cash flow) 270.75 K264.6 K207.15 K153.3 K35.17 K84 K —